MiniMed Group, Inc. specializes in the design and commercialization of medical equipment for individuals with Type 1 and Type 2 diabetes. The company's product portfolio features Automated Insulin Delivery (AID) systems, which integrate glucose sensing with automated insulin dosing, and Smart Multiple Daily Injection (MDI) systems such as the InPen and Simplera. In addition to its durable hardware, MiniMed provides related consumables, infusion sets, and software platforms that help patients and healthcare providers monitor blood glucose levels. Operating in approximately 80 countries, the company serves a global patient base with over 640,000 insulin pump users. Following nearly 25 years as a subsidiary of Medtronic, MiniMed completed its initial public offering in 2026 to operate as a standalone entity.
